These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Study on immunogenicity of a recombinant adenovirus vaccine containing neuraminidase gene of H5N1 influenza virus (A/Anhui/1/2005) in mice]. Ma J, Zhang XG, Li KB, Zhang XM, Wang M, Bai T, Yang L, Xu H, Shu YL, Zeng Y. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Dec; 23(6):449-51. PubMed ID: 20718353 [Abstract] [Full Text] [Related]
24. Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection. Eichelberger MC, Monto AS. J Infect Dis; 2019 Apr 08; 219(Suppl_1):S75-S80. PubMed ID: 30715357 [Abstract] [Full Text] [Related]
25. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses. Du N, Li W, Li Y, Liu S, Sui Y, Qu Z, Wang Y, Du Y, Xu B. Vaccine; 2008 Jun 02; 26(23):2912-8. PubMed ID: 18448208 [Abstract] [Full Text] [Related]
26. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens. Jadhao SJ, Lee CW, Sylte M, Suarez DL. Vaccine; 2009 Oct 19; 27(44):6247-60. PubMed ID: 19686695 [Abstract] [Full Text] [Related]
27. The protection of ferrets against influenza by immunization with a split influenza vaccine. Brady MI, Furminger IG. Dev Biol Stand; 1975 Oct 19; 28():167-72. PubMed ID: 1126566 [Abstract] [Full Text] [Related]
28. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. Takahashi Y, Hasegawa H, Hara Y, Ato M, Ninomiya A, Takagi H, Odagiri T, Sata T, Tashiro M, Kobayashi K. J Infect Dis; 2009 Jun 01; 199(11):1629-37. PubMed ID: 19385735 [Abstract] [Full Text] [Related]
29. Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE. Creskey MC, Li C, Wang J, Girard M, Lorbetskie B, Gravel C, Farnsworth A, Li X, Smith DG, Cyr TD. Vaccine; 2012 Jul 06; 30(32):4762-70. PubMed ID: 22643214 [Abstract] [Full Text] [Related]
30. Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children. Beutner KR, Rizzone C, DeMello S, Ogra PL. Dev Biol Stand; 1976 Jul 06; 33():162-70. PubMed ID: 782964 [Abstract] [Full Text] [Related]
31. In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Wohlbold TJ, Krammer F. Viruses; 2014 Jun 23; 6(6):2465-94. PubMed ID: 24960271 [Abstract] [Full Text] [Related]
32. Antigenic characterization of influenza viruses produced using synthetic DNA and novel backbones. Suphaphiphat P, Whittaker L, De Souza I, Daniels RS, Dormitzer PR, McCauley JW, Settembre EC. Vaccine; 2016 Jul 12; 34(32):3641-8. PubMed ID: 27219338 [Abstract] [Full Text] [Related]
33. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP. Pediatrics; 2007 Sep 12; 120(3):e553-64. PubMed ID: 17698577 [Abstract] [Full Text] [Related]
34. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. Johansson BE, Moran TM, Bona CA, Popple SW, Kilbourne ED. J Immunol; 1987 Sep 15; 139(6):2010-4. PubMed ID: 3624874 [Abstract] [Full Text] [Related]
35. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J. Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689 [Abstract] [Full Text] [Related]
36. Progress in the Development of Universal Influenza Vaccines. Sun W, Luo T, Liu W, Li J. Viruses; 2020 Sep 17; 12(9):. PubMed ID: 32957468 [Abstract] [Full Text] [Related]
37. [Antibody response to trivalent anti-influenza vaccination (inactivated virus) A/Texas/1/77 H3N2), A/URSS/90/77 (H1N1), B/Hong Kong/8/73]. Mancini G, Andreoni M, Arangio-Ruiz G, Sarrecchia C, Donatelli I, Resta S, Rozera C, Sordillo P, Rocchi G. Boll Ist Sieroter Milan; 1982 May 17; 61(2):85-91. PubMed ID: 7126342 [Abstract] [Full Text] [Related]
38. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. Muhamed G, Greenbaum E, Zakay-Rones Z. Isr Med Assoc J; 2006 Mar 17; 8(3):155-8. PubMed ID: 16599048 [Abstract] [Full Text] [Related]
39. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM. Vaccine; 2007 May 10; 25(19):3871-8. PubMed ID: 17337102 [Abstract] [Full Text] [Related]
40. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Sylte MJ, Hubby B, Suarez DL. Vaccine; 2007 May 10; 25(19):3763-72. PubMed ID: 17350145 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]